Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine

Vaccine

Volumn 32, Issue 30, 2014, Pages 3869-3876

  Rockman, Steve ^a   Becher, Dorit ^b   Dyson, Allison ^b   Koernig, Sandra ^b   Morelli, Adriana Baz ^b   Barnden, Megan ^b   Camuglia, Sarina ^a   Soupourmas, Peter ^b   Pearse, Martin ^b   Maraskovsky, Eugene ^b  

^a BioCSL   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

Adverse events; Cytokines; Febrile reactions; Lipid; NF kapaB; RNA; Seasonal trivalent influenza vaccine; Split viral complexes

Indexed keywords

2 AMINOPURINE; APC PROTEIN; BAFILOMYCIN A1; CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLUENZA VACCINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; LIPOFECTAMINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE R; RIBONUCLEASE A; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; DRUG CARRIER;

ARTICLE; CYTOKINE RELEASE; DRUG FEVER; HEK293 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLUENZA; INNATE IMMUNITY; PRIORITY JOURNAL; AUSTRALIA; CHEMICALLY INDUCED; EPIDEMIOLOGY; FEBRILE CONVULSION; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; INFLUENZA, HUMAN; METABOLISM; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD;

AUSTRALIA; CHEMOKINES; CHILD, PRESCHOOL; CYTOKINES; DRUG CARRIERS; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LIPIDS; NF-KAPPA B; PRODUCT SURVEILLANCE, POSTMARKETING; RNA, VIRAL; SEIZURES, FEBRILE;

EID: 84922213140     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.035     Document Type: Article

References (26)

1. CDC Seasonal influenza vaccine safety: a summary for clinicians 2013, http://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm.
2. Hambidge S.J., Glanz J.M., France E.K., McClure D., Xu S., Yamasaki K., et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. J Am Med Assoc 2006, 296:1990-1997.
3. Ohmit S.E., Gross J., Victor J.C., Monto A.S. Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination. Vaccine 2009, 27:1050-1054.
4. Dinarello C.A. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004, 10:201-222.
5. Blatteis C.M., Sehic E., Li S. Pyrogen sensing and signaling: old views and new concepts. Clin Infect Dis 2000, 31(Suppl. 5):S168-S177.
6. Netea M.G., Van der Meer J.W., Kullberg B.J. Recognition of pathogenic microorganisms by Toll-like receptors. Drugs Today (Barc) 2006, 42(Suppl. A):99-105.
7. Armstrong P.K., Dowse G.K., Effler P.V., Carcione D., Blyth C.C., Richmond P.C., et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011, 1:e000016.
8. Blyth C.C., Currie A.J., Wiertsema S.P., Conway N., Kirkham L.A., Fuery A., et al. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. Vaccine 2011, 29:5107-5113.
9. Rockman S., Dyson A., Koernig S., Becher D., Ng M., Baz Morelli A., et al. Introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine associated with adverse events. Vaccine 2013, [Submitted for publication].
10. Bennett I.L., Wagner R.R., Le Q.V. Pyrogenicity of influenza virus in rabbits. Proc Soc Exp Biol Med Soc Exp Biol Med 1949, 71:132.
11. Wagner R.R., Bennett I.L., Le Q.V. The production of fever by influenzal viruses; factors influencing the febrile response to single injections of virus. J Exp Med 1949, 90:321-334.
12. Bennett I.L., Wagner R.R., Le Q.V. The production of fever by influenzal viruses; tolerance in rabbits to the pyrogenic effect of influenzal viruses. J Exp Med 1949, 90:335-347.
13. Pickering J.M., Smith H., Sweet C. Influenza virus pyrogenicity: central role of structural orientation of virion components and involvement of viral lipid and glycoproteins. J Gen Virol 1992, 73(Pt 6):1345-1354.
14. Welty P.B., Epstein B., O'Brien J., Brackett R.G., Brandon F.B., Shillis J.L. Reactions and serologic responses after administration of inactivated monovalent influenza A/swine virus vaccines. I. Immunization of children and adults with influenza A/Shope virus vaccines. J Infect Dis 1977, 136(Suppl):S604-S608.
15. Bernstein D.I., Zahradnik J.M., DeAngelis C.J., Cherry J.D. Influenza immunization in children and young adults: clinical reactions and total and IgM antibody responses after immunization with whole-virus or split-product influenza vaccines. Am J Dis Child 1982, 136:513-517.
16. Bernstein D.I., Zahradnik J.M., DeAngelis C.J., Cherry J.D. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics 1982, 69:404-408.
17. Houde M., Arora D.J. Human influenza virus neuraminidase, but not hemagglutinin, induces murine macrophage interleukin 1 in vivo and in vitro. Immunol Lett 1989, 22:41-46.
18. Houde M., Arora D.J. Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase. Cell Immunol 1990, 129:104-111.
19. Maraskovsky E., Rockman S., Dyson A., Koernig S., Becher D., Baz Morelli A., et al. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere trivalent influenza vaccine. Vaccine 2011, 30:7400-7406.
20. Poland G.A., Fleming D.M., Treanor J.J., Maraskovsky E., Luke T.C., Ball E.M., et al. New wisdom to defy an old enemy: summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain. Vaccine 2013, 31(Suppl. 1):A1-A20.
21. Raetz C.R. Bacterial endotoxins: extraordinary lipids that activate eucaryotic signal transduction. J Bacteriol 1993, 175:5745-5753.
22. Ichinohe T. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design. Expert Rev Vaccines 2010, 9:1315-1324.
23. Pichlmair A., Schulz O., Tan C.P., Naslund T.I., Liljestrom P., Weber F., et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314:997-1001.
24. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
25. Brusick D.J. The genetic properties of beta-propiolactone. Mutat Res 1977, 39:241-255.
26. Fuminger I.G.S. Vaccine production. Textbook of influenza 1998, 324-332. Blackwell Science, Oxford. K.G. Nicholson, R.G. Webster, A.J. Hay (Eds.).